Uso de plasma rico em plaquetas autólogo na alopécia androgenética em mulheres: uma revisão sistemática e meta-análise

Detalhes bibliográficos
Ano de defesa: 2021
Autor(a) principal: Oliveira, Antônio Flávio Queiroz de
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Não Informado pela instituição
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: http://www.repositorio.ufc.br/handle/riufc/59918
Resumo: Androgenetic alopecia (AGA) affects up to 30% of older females and is the main cause of hair loss in adult women. AGA can severely impact on a woman’s quality of life and emotional well-being. Few studies have directly queried the use of autologous plateletrich plasma (PRP) as treatment option in females. To conduct a systematic review and meta-analysis to verify the efficacy of using autologous PRP in female pattern alopecia.MEDLINE / PubMed, Cochrane Library, ClinicalTrials.gov and EMBASE up to May 2021. We identified all studies evaluating the effect of PRP in female pattern alopecia. A narrative synthesis was performed from data on the efficacy of PRP treatment and adverse effects; quantitative results of PRP use compared to control treatment for female AGA were synthesized. The outcomes analyzed were terminal density and hair thickness.Seven articles were selected for this review. Meta-analysis showed that PRP-based interventions were able to increase terminal hair density compared to control (SMD = 2.98, 95% CI = 1.10, 4.85), with no significant increase in hair thickness (SMD = 1.16, 95% CI = -0.96, 3.28). During and after treatment, no major side effects were reported by patients or researchers.The use of autologous PRP injections in female AGA seems to be promising, with more consistent results on terminal hair density. However, caution is recommended in the interpretation of these results until they can be replicated in larger and more representative samples. PROSPERO registration number CRD42021257154.